Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1094975
Max Phase: Preclinical
Molecular Formula: C17H20N5O8P
Molecular Weight: 453.35
Molecule Type: Small molecule
Associated Items:
ID: ALA1094975
Max Phase: Preclinical
Molecular Formula: C17H20N5O8P
Molecular Weight: 453.35
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Nc1nc2c(c(=O)[nH]1)[n+](Cc1ccccc1)cn2[C@@H]1O[C@H](COP(=O)([O-])O)[C@@H](O)[C@H]1O
Standard InChI: InChI=1S/C17H20N5O8P/c18-17-19-14-11(15(25)20-17)21(6-9-4-2-1-3-5-9)8-22(14)16-13(24)12(23)10(30-16)7-29-31(26,27)28/h1-5,8,10,12-13,16,23-24H,6-7H2,(H4-,18,19,20,25,26,27,28)/t10-,12-,13-,16-/m1/s1
Standard InChI Key: WMKJRKYLDWLLPS-XNIJJKJLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 453.35 | Molecular Weight (Monoisotopic): 453.1049 | AlogP: -2.26 | #Rotatable Bonds: 6 |
Polar Surface Area: 199.86 | Molecular Species: ACID | HBA: 10 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 13 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 1.22 | CX Basic pKa: | CX LogP: -5.12 | CX LogD: -7.47 |
Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.20 | Np Likeness Score: 0.73 |
1. Jia Y, Chiu TL, Amin EA, Polunovsky V, Bitterman PB, Wagner CR.. (2010) Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP., 45 (4): [PMID:20060622] [10.1016/j.ejmech.2009.11.054] |
2. Chen X, Kopecky DJ, Mihalic J, Jeffries S, Min X, Heath J, Deignan J, Lai S, Fu Z, Guimaraes C, Shen S, Li S, Johnstone S, Thibault S, Xu H, Cardozo M, Shen W, Walker N, Kayser F, Wang Z.. (2012) Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction., 55 (8): [PMID:22458568] [10.1021/jm300037x] |
3. Golojuch S, Kopcial M, Strzelecka D, Kasprzyk R, Baran N, Sikorski PJ, Kowalska J, Jemielity J.. (2020) Exploring tryptamine conjugates as pronucleotides of phosphate-modified 7-methylguanine nucleotides targeting cap-dependent translation., 28 (13): [PMID:32362385] [10.1016/j.bmc.2020.115523] |
Source(1):